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Depressive Symptoms in Subjects With Diagnosed and Undiagnosed
Type 2 Diabetes
MIRJAM J. KNOL, MSC, EIBERT R. HEERDINK, PHD, ANTOINE C. G. EGBERTS, PHARMD, PHD, MIRJAM I. GEERLINGS, PHD,
KEES J. GORTER, MD, PHD, MATTIJS E. NUMANS, MD, PHD, DIEDERICK E. GROBBEE, MD, PHD,
OLAF H. KLUNGEL, PHARMD, PHD, AND HUIBERT BURGER, MD, PHD
Objective: To investigate if disturbed glucose homeostasis or known diagnosis of diabetes was associated with depressive
symptoms. The reason for the increased prevalence of depression in patients with Type 2 diabetes mellitus (DM2) is unknown.
Methods: Within the Utrecht Health Project, an ongoing longitudinal study among inhabitants of a residential area of a large city
in The Netherlands, 4747 subjects (age: 39.4  12.5 years) were classified into four mutually exclusive categories: normal fasting
plasma glucose (FPG) (5.6 mmol/l), impaired FPG (5.6 and 7.0 mmol/l), undiagnosed DM2 (FPG 7.0 mmol/l), and
diagnosed DM2. Presence of depressive symptoms was defined as a score of25 on the depression subscale of the Symptom Check
List (SCL-90) or self-reported use of antidepressants. Results: Diagnosed DM2 was associated with an increased risk of depressive
symptoms (odds ratio (OR)  1.69; 95% confidence interval (CI) 1.06–2.72) after adjustment for demographic and lifestyle
variables. Additional adjustment for number of chronic diseases reduced the OR to 1.36 (95% CI 0.83–2.23). Impaired fasting
glucose and undiagnosed DM2 were not associated with depressive symptoms. Conclusions: Our findings suggest that disturbed
glucose homeostasis is not associated with depressive symptoms. The increased prevalence of depressive symptoms among patients
with diagnosed DM2 suggests that depressive symptoms might be a consequence of the burden of diabetes. The number of chronic
diseases seems to explain part of the association between DM2 and depressive symptoms. Key words: depressive symptoms,
diabetes, blood glucose, burden.
DM2  Type 2 diabetes mellitus; CI  confidence interval; DSM-
IV  Diagnostic and Statistical Manual of Mental Disorders, fourth
revision; FPG  fasting plasma glucose; OR  odds ratio; SCID 
Structured Clinical Interview for DSM-IV; SCL-90  Symptom
Checklist; SD  standard deviation; SPSS  Statistical Package for
the Social Sciences; UHP  Utrecht Health Project.
INTRODUCTION
Diabetes and depression are both common conditions intoday’s society. There are about 200 million people with
diabetes worldwide (1) and an estimated 121 million people
currently suffer from depression (2). Diabetes and depression
are also often comorbid conditions. A recent meta-analysis
showed that the prevalence of depression is doubled in pa-
tients with Type 2 diabetes compared with subjects without
diabetes (3). However, the reason for the increased prevalence
among patients with diabetes is unknown. Also, the direction
of the association between Type 2 diabetes and depression is
not known. Recently, a meta-analysis of longitudinal studies
suggested that depression is a small risk factor for the onset of
Type 2 diabetes (4). However, depression is also often seen as
a consequence of Type 2 diabetes (5). In this paper, we will
focus on the latter.
There are two possible mechanisms underlying the associ-
ation between Type 2 diabetes and the onset of depression.
First, biochemical changes associated with diabetes could
account for the increased risk of depression (5). For example,
hyperglycemia and hyperinsulinemia increase the activity of
the hypothalamic-pituitary-adrenal axis, inducing arousal of
the nervous system, which in turn may promote depression
(6,7). Second, depression in patients with diabetes may be
viewed as the result of the burden of the disease (5,8). This is
supported by the finding that when the burden of diabetes
increases, the probability of mood symptoms increases as well
(9). Furthermore, an increased prevalence of depression is also
seen in patients with chronic diseases other than diabetes (10).
The aim of the present study was to investigate if disturbed
glucose homeostasis is associated with depressive symptoms
or if a known diagnosis of diabetes is associated with depres-
sive symptoms. We compared the prevalence of depressive
symptoms in four groups: subjects with normal fasting glu-
cose level; subjects with prediabetes, i.e., impaired fasting
glucose level; subjects who did not know they had Type 2
diabetes, but whose fasting plasma glucose (FPG) level indi-
cated the presence of diabetes; and subjects who know they
had Type 2 diabetes because their doctor diagnosed them.
PATIENTS AND METHODS
Study Population
The Utrecht Health Project (UHP) was a data source for this study (11).
The UHP is an ongoing longitudinal study, set up in 2000, among all
inhabitants of a new residential area of Utrecht, a large city in The Nether-
lands. Each new inhabitant who registered with a general practitioner (GP)
was invited by mail to participate in the study. In the Dutch healthcare system,
access to pharmacy care or secondary care is only possible via the GP.
Therefore, almost all inhabitants of The Netherlands are registered with a GP.
At baseline, an individual health profile is made for every participant that
includes an interview-assisted questionnaire, physical examination, and a
blood sample. The questionnaire includes questions about demographic fac-
tors, lifestyle factors, current health status, quality of life, psychopathology,
and disability. Physical examination includes measurements of weight, height,
and blood pressure. Blood assessment includes FPG and cholesterol level
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measurements. In the future, follow-up data on morbidity, medication, and
referrals will be obtained through the automated registry of all GPs and
pharmacists in the area.
The Medical Ethics Committee of the University Medical Center Utrecht
in The Netherlands approved the UHP. The UHP started to recruit participants
in 2001 and, since then, response has been steadily increasing. By January
2005, 13,128 inhabitants were invited, of whom 6755 (51.4%) gave informed
consent. Baseline data were complete for 6304 (48.0%) participants, of whom
4950 were aged 18 years. Nonresponders were more often male (51.5%
versus 45.9%) and nonresponders were younger than responders (mean age
(SD): 36.5 years (12) versus 38.7 years (13)). Reasons for not participating in
the study were a) not interested in the study (44%); b) no recognition of
personal advantage in participating (26%); and c) too busy (14%). A small
group did not want to participate in scientific research from conviction (2%);
others had practical reasons for not participating (14%).
The current analysis is based on baseline data of 4950 subjects aged 18
years.
FPG and Diabetes
First, subjects who reported having been diagnosed with diabetes by a
physician were classified as having “diagnosed diabetes.” Second, the remain-
ing subjects were, according to the latest American Diabetes Association
criteria (12), categorized based on their FPG concentration into a) normal
FPG (5.6 mmol/l); b) impaired FPG (5.6 and 7.0 mmol/l); and c)
undiagnosed diabetes (7.0 mmol/l). Fasting glucose values were obtained
from a venous blood sample. In 178 subjects, a finger prick sample was
obtained instead of a venous blood sample, producing whole blood glucose
values. These whole blood values were converted into venous values by
multiplying with factor 1.11 (13). Some patients were not fasting when the
blood sample was obtained. If subjects had a nonfasting blood glucose value
which was increased (5.6 mmol/l), they were excluded from further anal-
yses (n  22). Patients with diagnosed diabetes who used insulin and no oral
hypoglycemic agents were defined as having Type 1 diabetes and were
excluded (n  14) from the study.
Depressive Symptoms
Depressive symptoms were assessed with a psychopathology question-
naire, the Symptom Check List (SCL-90) (14,15). The SCL-90, a self-rated
scale, consists of eight psychiatric symptom domains, including a 16-item
depression subscale. Each item is scored on a 5-point scale. In this study, the
presence of depressive symptoms was defined as a score of 25 on the
depression subscale. A validation study showed that this cut-off point was
the optimal cut-off point with a sensitivity of 88.5 and a specificity of 60.7
when compared with the depression section of the Structured Clinical Inter-
view for Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
(SCID) (16). Another study showed that a cut-off point of 25 gave a sensi-
tivity of 95.5 and a specificity of 74.0 for major depression 1 month after a
myocardial infarction, also with the SCID as the gold standard (17).
In addition, subjects reporting use of antidepressants were classified as
having depressive symptoms irrespective of their score on the SCL-90.
Subjects who used antidepressants for a nonpsychiatric indication (n  3),
such as pain and incontinence, were recoded as “not using antidepressants.”
Covariates
Before performing the analyses, we selected gender, age, education level,
body mass index, smoking, alcohol consumption, physical activity, and the
number of chronic diseases as potential confounders. Information on gender,
age, highest attained education level, smoking, alcohol consumption, physical
activity (number of days for30 minutes), and chronic diseases was collected
with a self-report questionnaire. We categorized education level as follows: a)
low (no education, primary school, or lower vocational training); b) interme-
diate (general secondary school or intermediate vocational training); and c)
high (higher vocational training or university). Smoking was categorized as
never, current, and former smoking. Alcohol consumption was assessed with
number, frequency, and type of alcoholic drinks. Alcohol consumption was
categorized as 0 glasses per day, 1 to 2 glasses per day, and 2 glasses per
day. To assess the level of physical activity, the number of days with at least
half an hour of physical activity (including cycling, gardening, or sports) in
leisure time was used.
Chronic diseases that were present during the last year and diagnosed by
a physician included asthma, chronic obstructive pulmonary disease, severe
heart disease, myocardial infarction, stroke, cancer, osteoarthritis, and rheumatoid
arthritis. Weight and height were measured and body mass index was calculated.
Data Analysis
Relative risks of depressive symptoms for subjects with impaired FPG
concentrations, undiagnosed, and diagnosed Type 2 diabetes were estimated
using logistic regression and were expressed as odds ratios (ORs) with 95%
confidence intervals (CIs). Model 0 shows the crude ORs. In model 1, we
adjusted for gender, age, and education level. In model 2, we added body mass
index, smoking status (never, current, former), alcohol consumption, and
physical activity to the model. In model 3, the number of chronic diseases,
other than diabetes, was added to the model. These covariates were selected
before the analyses. Gender, education level, smoking status, and alcohol
consumption were included as categorical covariates. Age, body mass index,
physical activity, and number of chronic diseases were included as continuous
covariates. We performed the goodness-of-fit test as a measure of model fit.
Only 2.3% of the data we used was missing. However, if we performed
complete case analysis, we lost 1168 (24.6%) subjects, as these subjects had
missing values on1 variables. Missing data can severely affect the power of
statistical analyses because patients with incomplete data are typically ex-
cluded. Furthermore, complete case analysis can give biased results because
nonresponse is usually selective. Therefore, in the present study, multiple
imputation (18) was used to fill in missing values under the assumption that
these values only depend on observed values (missing at random). Five
complete datasets were created, using the library Multivariate Imputation by
Chained Equations (19) in the statistical package S-PLUS 2000. Although it
depends on the percentage of missing data as to how many datasets should be
created, in many applications three to five imputations are sufficient to obtain
excellent results (20). Subsequently, logistic regression modeling was per-
formed on each dataset, and the regression coefficients of the five models
were pooled.
We reasoned that adjusting for cardiovascular disease in the model might
not be appropriate because a cardiovascular condition could, in part, be an
intermediate factor in the association between Type 2 diabetes and depressive
symptoms. Therefore, we performed an additional analysis in which we
excluded 79 subjects who reported severe heart disease, myocardial infarc-
tion, or stroke.
All analyses were performed with SPSS version 12.0 (SPSS Inc., Chicago,
IL) or S-PLUS 6.2 (Insightful Corp., Seattle, WA).
RESULTS
The source population consisted of 4950 subjects aged 18
years. Questionnaire data were completely missing from 167
subjects and these subjects were excluded (mean age: 35.4 years
(SD  11) and 46.7% male subjects). Twenty-two subjects with
only nonfasting plasma glucose concentration available and 14
subjects with Type 1 diabetes were excluded, leaving 4747 sub-
jects in the study population. Of these subjects, 2121 (44.7%)
were male and 2626 (55.3%) were female; they had a mean age
of 39.4 (SD  12.5) years. In this population, the prevalence
(95% CI) of impaired fasting glucose, undiagnosed, and diagnosed
Type 2 diabetes was 15.5% (14.4%–16.6%), 1.3% (0.96%–1.6%),
and 2.4% (1.9%–2.9%), respectively. The overall prevalence (95%
CI) of depressive symptoms (including antidepressant use) was
19.3% (18.2%–20.4%). These percentages are the observed preva-
lences, i.e., before imputation.
Table 1 presents the subject characteristics in the four
subgroups before multiple imputation was performed and the
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numbers of missing values. In 385 subjects, information on
FPG concentration and diagnosed diabetes was missing and,
in 77 subjects, depressive symptom score or information on
antidepressant use was missing. Gender ratio, age, education
level, and body mass index differed considerably among the
four subgroups. All chronic diseases were most prevalent in
the patients with diagnosed Type 2 diabetes. Mean depressive
symptom score was highest in the group with diagnosed diabetes,
whereas the percentage of subjects who used antidepressants was
lowest in this group. The prevalence of depressive symptoms,
defined as a score of 25 on the depression subscale of the
SCL-90, use of antidepressants, or both, was 20.0% in the pa-
tients with undiagnosed diabetes and 29.7% in the patients with
diagnosed Type 2 diabetes. Mean FPG levels were similar in the
undiagnosed patients as well as the patients with diagnosed Type
2 diabetes, although the variance was higher in the patients with
diagnosed diabetes.
Table 2 presents the crude and adjusted ORs and 95% CIs
of depressive symptoms for impaired FPG concentration and
undiagnosed and diagnosed Type 2 diabetes. These are the
effect estimates after multiple imputation was performed.
Therefore, the numbers of subjects in the exposure groups are







N 3499 671 55 102
Gender, % male 40.4 63.6 43.6 52.9
n missing 0 0 0 0
Age, mean  SD 37.7  11.3 46.7  13.9 56.9  12.7 55.8  14.4
n missing 0 0 0 0
Education
% low 17.1 28.5 51.9 44.9
% middle 42.9 43.9 34.6 40.8
% high 40.0 27.6 13.5 14.3
n missing 114 19 3 4
BMI (kg/m2), mean  SD 24.9  4.0 27.7  4.3 29.2  6.1 28.1  4.6
n missing 6 1 0 0
Smoking
% current 23.5 26.8 16.4 20.6
% former 28.1 37.3 58.2 41.2
n missing 36 7 0 0
Alcohol use, %
0 glasses/day 23.5 21.4 33.3 42.9
% 1–2 glasses/day 60.5 53.9 43.1 38.8
% 2 glasses/day 15.9 24.7 23.5 18.4
n missing 106 35 4 4
Physical activity (days/week), mean  SD 3.2  2 3.2  2 3.3  3 3.3  2
n missing 255 61 4 12
Asthma/COPD, % 8.8 12.5 3.6 17.8
n missing 42 5 0 1
Severe heart disease or MI, % 0.6 2.4 3.6 9.8
n missing 41 7 1 5
Stroke, % 0.4 0.9 0.0 6.1
n missing 40 4 0 3
Cancer, % 0.5 2.0 1.8 5.9
n missing 38 10 0 1
Osteoarthritis, % 6.0 14.0 27.3 29.9
n missing 57 7 0 5
Arthritis, % 3.9 6.1 9.1 17.7
n missing 85 13 0 6
Depressive symptom score, mean  SD 21.0  7.2 20.8  7.1 20.9  6.3 23.0  9.2
Median (range) 18.0 (16–77) 18.0 (16–62) 19.0 (16–46) 19.0 (16–64)
n missing 52 10 0 1
Use of antidepressants, % 2.5 3.6 3.6 2.0
n missing 19 6 0 0
Depressive symptoms,a % 19.4 17.5 20.0 29.7
n missing 63 13 0 1
Fasting plasma glucose, mean  SD 4.9  0.4 5.9  0.3 8.3  2.1 8.3  3.3
n missing 0 0 0 7
a Defined as score of 25 on depression subscale of SCL-90 and/or self-reported use of antidepressants.
FPG  fasting plasma glucose; DM2  Type 2 diabetes mellitus; SD  standard deviation; BMI  body mass index; COPD  chronic obstructive pulmonary
disease; MI  myocardial infarction.
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higher than the numbers presented in Table 1. Compared with
the normal glucose group, the odds of depressive symptoms
was not higher in the impaired glucose group (OR  0.90
(0.72–1.12)) and the patients with undiagnosed Type 2 diabe-
tes (OR  1.00 (0.51–1.96)) (model 0). Adjustment for de-
mographic, lifestyle variables, and the number of chronic
diseases did not change this finding. In the diagnosed Type 2
diabetes group, however, the odds of depressive symptoms
was increased (OR  1.79 (1.17–2.75); model 0). Adjustment
for gender, age, education level, body mass index, smoking
status, alcohol consumption, and physical activity did not
change this risk estimate (model 2). Adding the number of
chronic diseases to the model lowered the OR for diagnosed
Type 2 diabetes (OR  1.36 (0.83–2.23); model 3). The
model adjusted for all demographic and lifestyle variables
(model 2) and the model additionally adjusted for the number
of chronic diseases (model 3) showed no deviance of good-
ness-of-fit with p values of .47 and .29, respectively. Model 1
did show deviance of goodness-of-fit with p  .01, but we
considered this less relevant as this was not our primary model
of interest.
When excluding 79 subjects with cardiovascular disease,
the ORs for the impaired fasting glucose group and the pa-
tients with undiagnosed diabetes were comparable with those
presented in Table 2 (data not shown). For the patients with
diagnosed Type 2 diabetes, the ORs were slightly higher than
when subjects with cardiovascular disease were not excluded:
when adjusting for gender, age, and education (model 1), the
OR for patients with diagnosed Type 2 diabetes was 1.92
(95% CI  1.17–3.14). Additional adjustment for lifestyle
factors (model 2) resulted in an OR of 1.95 (95% CI 
1.18–3.22). The OR was 1.77 (95% CI  1.06–2.96) when
adjusting for the number of (other) chronic diseases (model 3).
In the results presented above, we categorized the FPG
levels into three groups, which reflect clinical practice. We
performed a post hoc analysis where we included FPG level as
a continuous variable and diagnosis of diabetes as a dichoto-
mous variable into the model. The crude OR (95% CI) for
continuous FPG (per 1 mmol/l increase) was 0.91 (0.83–1.01)
and the crude OR for a diagnosis of diabetes was 2.38 (95%
CI  1.43–3.95). Adjusting for age, gender, and education
level (model 1) changed the OR into 0.98 (95% CI  0.89–
1.07) and 1.79 (95% CI  1.07–3.01). Additional adjustment
for lifestyle factors and the number of chronic diseases (model
3) resulted in an OR for fasting plasma glucose level of 0.99
(95% CI  0.90–1.09) and for a diagnosis of diabetes of 1.40
(95% CI  0.81–2.41). Again, models 2 and 3 did not show
deviance of goodness-of-fit and model 1 showed deviance of
goodness-of-fit. These results are similar to the results described
above; namely, having a diagnosis of diabetes increased the risk
of depressive symptoms whereas no association was seen be-
tween FPG and depressive symptoms.
DISCUSSION
In the present study, subjects with impaired FPG concentra-
tion and undiagnosed Type 2 diabetes did not have an increased
risk of depressive symptoms. Patients with diagnosed Type 2
diabetes had a 1.7 times increased risk of depressive symptoms
compared with subjects with normal glucose concentrations after
adjustment for demographic and lifestyle variables. After addi-
tional adjustment for number of chronic diseases, the risk of
depressive symptoms was no longer significantly increased in
patients with diagnosed diabetes.
These results suggest that disturbed glucose homeostasis is
not associated with depressive symptoms. As subjects aware
of their diabetes had an increased risk of depressive symptoms
and subjects unaware of their diabetes had not, the increased
risk of depressive symptoms in diabetes might be a conse-
quence of its burden rather than a consequence of high glucose
levels. The number of comorbid chronic diseases explains part
of the increased prevalence seen in patients with diagnosed
Type 2 diabetes.
Depressive symptoms might be a consequence of diag-
nosed diabetes. However, as this study has a cross-sectional
design, we cannot distinguish between causes and conse-
quences. Diagnosed diabetes can also be a consequence of
having depressive symptoms. This may occur if subjects with
depressive symptoms are more likely to be diagnosed with
Type 2 diabetes because they more often consult a physician,
i.e., detection bias.
It is possible that we found a high prevalence of depressive
symptoms in the patients with diagnosed Type 2 diabetes and
TABLE 2. Association of Impaired Fasting Plasma Glucose Concentration, Undiagnosed, and Diagnosed Type 2 Diabetes With Depressive
Symptoms, Expressed as Crude and Adjusted Odds Ratio (95% Confidence Interval) (After Multiple Imputation)
Normal FPG
(5.6; N  3853)
Impaired FPG
(5.6 and 7.0; N  732)
Undiagnosed DM2
(FPG 7.0; N  58)
Diagnosed DM2
(N  104)
Model 0a 1.00 0.90 (0.72–1.12) 1.00 (0.51–1.96) 1.79 (1.17–2.75)
Model 1b 1.00 1.03 (0.81–1.31) 0.84 (0.42–1.69) 1.70 (1.07–2.70)
Model 2c 1.00 1.01 (0.78–1.29) 0.82 (0.40–1.68) 1.69 (1.06–2.72)
Model 3d 1.00 0.99 (0.77–1.27) 0.86 (0.42–1.77) 1.36 (0.83–2.23)
a Reference category.
b Adjusted for gender, age, and education.
c Adjusted for gender, age, education, body mass index, current and former smoking, alcohol consumption, and physical activity.
d Adjusted for gender, age, education, body mass index, current and former smoking, alcohol consumption, physical activity, and number of chronic diseases.
FPG  fasting plasma glucose; DM2  Type 2 diabetes mellitus.
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not in subjects in earlier stages of diabetes because patients
with diagnosed diabetes have a higher level and longer dura-
tion of disturbed glucose homeostasis. Although, if this were
the case, we would expect to see a trend between increasing
glucose levels and depressive symptoms, which we did not.
Our findings support those of Palinkas et al. (21), who
showed an increased prevalence of depression in patients with
previously diagnosed Type 2 diabetes and no increased prev-
alence in patients unaware of their diabetes, suggesting that
depression develops after a diagnosis of diabetes. The almost
two-fold increased prevalence of depressive symptoms we
observed in patients with diagnosed Type 2 diabetes is also in
accordance with the results of a meta-analysis, showing an OR
of 2 when pooling 20 cross-sectional studies (3). Further, our
finding of the absence of an association between fasting
glucose concentrations and depressive symptoms is not incon-
sistent with the results of two recent studies showing a nega-
tive (22) and a positive association (23) between insulin
resistance and depression. Also, in a recent prospective study
on insulin resistance and depressive symptoms in middle aged
men, no association was found (24). However, in that study,
no association between clinically manifest diabetes and de-
pressive symptoms was found either. Another prospective
study showed no association between patients with diagnosed
diabetes and those with depressive symptoms (25).
Two recent studies on factors associated with depression in
Type 2 diabetes showed that patients with diabetes and comorbid
chronic somatic diseases had an increased prevalence of depres-
sion, whereas those without diabetes did not (26,27). In our
study, the number of chronic diseases also explained part of the
increased prevalence of depressive symptoms in patients with
diagnosed Type 2 diabetes. Interestingly, a prospective study
showed no increased risk of developing depression in patients
with diabetes compared with those with osteoarthritis (28). This
suggests nonspecificity of diabetes as a risk factor for depression
and is consistent with our finding that depression in patients with
diabetes may be a consequence of the burden of the disease rather
than a result of physiologic changes due to high glucose levels.
Some limitations of our study need to be addressed. First,
we used self-report to define diagnosis of Type 2 diabetes. It
is possible that some misclassification occurred in that pa-
tients with diagnosed diabetes misclassified themselves as not
diagnosed. Yet, a Dutch validation study showed that self-
reported diagnosis of diabetes is in good agreement with a
physician diagnosis (29). Furthermore, if misclassification
was random, the relative risk of depressive symptoms in
patients with diagnosed diabetes we estimated is an underes-
timation. Type 1 diabetes was defined as use of insulin and no
use of oral hypoglycemic agents; we excluded 14 subjects
based on this definition. It is possible that some of these
subjects were patients with Type 2 diabetes after all. An
additional analysis showed that including or excluding these
subjects did not change the association between diagnosed
diabetes and depressive symptoms.
Second, we did not use a diagnostic interview to confirm
depression according to the DSM-IV criteria. However, our
aim was to compare different groups regarding depressive
symptom level and not to obtain precise estimates of the
prevalence of depression in these groups. Analyzing the de-
pression score continuously might have given more power to
detect an association. However, we used the validated cut-off
point of 25 described in the literature (16,17). Also, two
practical reasons to dichotomize the depressive symptom
score were that the variable was not normally distributed,
which could not be solved by several transformations, and that
we also included users of antidepressant medication into the
depressive symptom group. Regarding the cut-off point of 25,
one study also suggested a cut-off point of 27 for major and
minor depression with a sensitivity of 81.1 and a specificity of
83.5 (17). Use of this more conservative cut-off point did not
change our findings.
Third, antidepressant use is not solely prescribed for de-
pression but also for other psychiatric problems such as anx-
iety and panic disorders; this prescription practice may have
confound our results. However, in our study, only 5.9% of the
subjects with depressive symptoms were defined as such
based on antidepressant use. Excluding subjects who used
antidepressants resulted in a slightly higher OR in the group
with diagnosed Type 2 diabetes. In addition, analyzing anti-
depressant use as a covariate, instead of as an indicator of
depression on the dependent variable side, did not change our
conclusion.
Fourth, as the response rate of the study was about 50%,
selection bias could have occurred. Nonresponders were more
often male and were younger than responders, which may
have influenced the prevalence of diabetes and depressive
symptoms but most likely not the association between diabe-
tes and depressive symptoms (30). Potential selection bias
through missing data was minimized because we performed
multiple imputation to impute missing values. Multiple impu-
tation is the preferred method to deal with missing values
because it leads to unbiased estimates and correct standard
errors as opposed to complete case analysis or single imputa-
tion techniques (31). Because our study population was
young, the number of patients with undiagnosed and diag-
nosed Type 2 diabetes was relatively low. Therefore, the study
may have had limited power. Regarding generalizability, our
results may not apply to an elderly population because of our
relatively young study population.
A strong aspect of our study is that we used a large sample
from the general population. Second, we adjusted for the most
important factors known from the literature that could disturb
the association between Type 2 diabetes and depressive symp-
toms. Third, the design of the UHP made it possible to
compare subjects who were unaware of their diabetes with
subjects who were aware of their diabetes within a single
population; therefore, we could make some inferences about
the reason for the increased prevalence of depressive symp-
toms in patients with Type 2 diabetes.
In conclusion, the results of the present study suggest that
disturbed glucose homeostasis is not associated with depres-
sive symptoms. The association we found between diagnosed
M. J. KNOL et al.
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diabetes and depressive symptoms suggests that the increased
prevalence of depressive symptoms in patients with Type 2
diabetes is a consequence of the burden of the disease. Fur-
thermore, the number of chronic diseases seems to partly
explain the association between diagnosed Type 2 diabetes
and depressive symptoms.
More research is needed to confirm the association between
Type 2 diabetes and depressive symptoms. Instead of cross-
sectional studies, longitudinal studies should be performed to
investigate if diabetes is an independent risk factor for the
onset of depressive symptoms. In these studies, the influence
of a history of depression and the influence of comorbid
chronic diseases should be taken into account. Furthermore,
future research should clarify if the onset of depressive symp-
toms is specific for Type 2 diabetes or if it is also present in
other chronic diseases. Finally, the mechanisms underlying
the association between diabetes and depression should be
investigated.
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